Literature DB >> 25901432

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Alessandro M Vannucchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25901432     DOI： 10.1056/NEJMc1502524

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  23 in total

Review 1.  JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Authors:  Lorraine Springuel; Jean-Christophe Renauld; Laurent Knoops
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

2.  Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study.

Authors:  Ali T Taher; Zeynep Karakas; Elena Cassinerio; Noppadol Siritanaratkul; Antonis Kattamis; Aurelio Maggio; Stefano Rivella; Norbert Hollaender; Bruyère Mahuzier; Brian Gadbaw; Yesim Aydinok
Journal:  Blood       Date:  2017-11-02       Impact factor: 22.113

Review 3.  Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.

Authors:  Ruochen Jia; Robert Kralovics
Journal:  Int J Hematol       Date:  2019-11-18       Impact factor: 2.490

Review 4.  Experience with ruxolitinib in the treatment of polycythaemia vera.

Authors:  Samah Alimam; Claire Harrison
Journal:  Ther Adv Hematol       Date:  2017-04-01

5.  Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study.

Authors:  A M Yesilova; S Yavuzer; H Yavuzer; M Cengiz; I D Toprak; E Hanedar; M C Ar; Z Baslar
Journal:  Int J Hematol       Date:  2016-10-03       Impact factor: 2.490

6.  Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms.

Authors:  Kaitlyn Shank; Andrew Dunbar; Priya Koppikar; Maria Kleppe; Julie Teruya-Feldstein; Isabelle Csete; Neha Bhagwat; Matthew Keller; Outi Kilpivaara; Franziska Michor; Ross L Levine; Laura de Vargas Roditi
Journal:  Haematologica       Date:  2019-08-14       Impact factor: 9.941

7.  Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.

Authors:  Jean-Jacques Kiladjian; Pierre Zachee; Masayuki Hino; Fabrizio Pane; Tamas Masszi; Claire N Harrison; Ruben Mesa; Carole B Miller; Francesco Passamonti; Simon Durrant; Martin Griesshammer; Keita Kirito; Carlos Besses; Beatriz Moiraghi; Elisa Rumi; Vittorio Rosti; Igor Wolfgang Blau; Nathalie Francillard; Tuochuan Dong; Monika Wroclawska; Alessandro M Vannucchi; Srdan Verstovsek
Journal:  Lancet Haematol       Date:  2020-01-23       Impact factor: 18.959

8.  Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors.

Authors:  Marissa A Zarakas; Jigar V Desai; Georgios Chamilos; Michail S Lionakis
Journal:  Curr Fungal Infect Rep       Date:  2019-07-05

Review 9.  Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature.

Authors:  Amy Zhou; Amber Afzal; Stephen T Oh
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 10.  Current Management of Chronic Neutrophilic Leukemia.

Authors:  Natasha Szuber; Ayalew Tefferi
Journal:  Curr Treat Options Oncol       Date:  2021-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.